You are here: Industry Insights > AstraZeneca

News List

AstraZeneca acquires Dogma Therapeutics’ PCSK9 inhibitor programme pharmaceutical-technology
September 18, 2020
AstraZeneca has signed an agreement to purchase a preclinical oral PCSK9 inhibitor programme from Dogma Therapeutics for an undisclosed amount.
AstraZeneca stops COVID-19 vaccine trial due to unexplained illness in participant expresspharma
September 18, 2020
A UK participant was found to have transverse myelitis, an inflammatory syndrome that affects the spinal cord and is often sparked by viral infections, according to a New York Times report.
DCGI issues notice to Serum Institute over AstraZeneca-Oxford COVID-19 vaccine trial suspension expresspharma
September 18, 2020
If DCGI has any safety concerns, we will follow their instructions and abide by the standard protocol, said SII in response to show cause notice.
Australia enters $1.2bn Covid-19 vaccine supply agreement pharmaceutical-technology
September 17, 2020
The Government of Australia has signed a supply and production agreement valued at A$1.7bn ($1.2bn) to potentially offer a free Covid-19 vaccine to its citizens next year.
AMRI to Provide Sterile Fill/Finish Mfg. for AstraZeneca’s COVID-19 Vax contractpharma
September 17, 2020
To supply the vaccine candidate AZD1222 from AMRI’s drug product manufacturing facility in Albuquerque, NM.
Clinical trial for AstraZeneca Oxford COVID-19 vaccine candidate to resume europeanpharmaceuticalreview
September 15, 2020
After the clinical trial for AZD1222 was halted last week, the studies for AstraZeneca’s COVID-19 vaccine candidate will now resume.
NICE backing for AZ' Tagrisso pharmatimes
September 15, 2020
AstraZeneca's Tagrisso (osimertinib) has been recommended for use within NHS England, in line with its licensed indication, for adults with untreated locally-advanced or metastatic epidermal growth factor receptor (EGFR) ...
Imfinzi approved in EU to treat extensive-stage small cell lung cancer europeanpharmaceuticalreview
September 14, 2020
Imfinzi (durvalumab) has been approved by the European Commission as a first-line treatment for extensive-stage small cell lung cancer, with chemotherapy.
AZ Fasenra shows benefit in chronic rhinosinusitis with nasal polyps pharmatimes
September 14, 2020
AstraZeneca’s Fasenra (benralizumab) significantly reduced the size of nasal polyps and cut nasal blockage in patients with chronic rhinosinusitis, raising hopes for a new treatment option for this condition.
Clinical Trial of AstraZeneca COVID-19 Vaccine Paused After Illness drugs.com
September 10, 2020
A "potentially unexplained" illness in a participant has led AstraZeneca to halt a late-stage clinical trial of its COVID-19 vaccine.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page